Advertisement

Topics

A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma

2014-08-27 04:00:41 | BioPortfolio

Summary

This is an open-label, dose-escalation, non-randomized, phase I study in patients with histologically confirmed Stage III or IV melanoma and at least three metastatic cutaneous or subcutaneous lesions suitable for: intralesional (IL) injection (1 lesion), accessible for biopsy (1 lesion), and response evaluation by RECIST (v1.1) and modified RECIST (irRC) (1 lesion). The primary objective is to determine whether IL administration of BCG followed by intravenous (IV) infusion of ipilimumab is safe. Ipilimumab (YERVOY®) is the monoclonal anti-CTLA-4 antibody approved by the FDA and TGA as anticancer therapy for melanoma. Secondary objectives of the study are: a) clinical efficacy, to document whether this combination therapy induces tumour responses; and b) immunogenicity, to identify if the combination induces immune responses against the tumours. All patients will be included in the analysis of efficacy and immunogenicity.

Cohort 1 (9 patients with <10mm induration after tuberculin Purified Protein Derivative [PPD] test): Group 1 (3 patients) will receive one IL injection of 200 µl BCG containing 0.16 - 0.64 x 106 cfu followed by four IV infusions of 3 mg/kg ipilimumab every 3 weeks, starting on day 36. Group 2 (3 patients) and 3 (n=3) will receive 200 µl BCG containing 0.8 - 3.2 x 106 cfu and 4.0 -16.0 x 106 cfu, respectively, followed by the same ipilimumab regimen. Safety will be evaluated in this cohort.

Cohort 2 (up to 9 patients with ≥10mm induration after PPD test): Enrolment will start after the final patient in Cohort 1, Group 1 has reached study week 7. Then enrolment can proceed in parallel for Cohort 2 and Cohort 1 Groups 2 and 3. Patients will receive 0.16 -0.64 x 106 cfu BCG followed by four IV infusions of 3 mg/kg ipilimumab every 3 weeks, starting on day 36. Evaluation of safety in this cohort will be observational.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Metastatic Melanoma

Intervention

Bacillus Calmette-Guérin (BCG) vaccine, Ipilimumab

Location

Austin Health, LICR Melbourne Austin Branch
Heidelberg
Victoria
Australia
2084

Status

Recruiting

Source

Ludwig Institute for Cancer Research

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T04:00:41-0400

Clinical Trials [3645 Associated Clinical Trials listed on BioPortfolio]

Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma

The purpose of this study is to determine if treatment with the autologous cellular vaccine, Melaxin, in combination with Bacillus Calmette-Guerin (BCG) injections is effective in Stage I...

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

The primary purpose of this study is to demonstrate that the NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab is safe for the treatment of patients with advanced or meta...

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

This study, with 20 patients participating, will examine the safety and tolerability for the ipilimumab/UV1 combination in patients with unresectable or metastatic malignant melanoma.

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

The purpose of this study is to determine whether giving Ipilimumab at a dose of 10mg/kg will extend the lives of subjects with unresectable or metastatic melanoma more than giving Ipilimu...

Ipilimumab + Temozolomide in Metastatic Melanoma

The goal of this clinical research study is to learn if combining Ipilimumab and Temozolomide can help to control metastatic melanoma. The safety of this drug combination will be studied....

PubMed Articles [4159 Associated PubMed Articles listed on BioPortfolio]

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Brain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melanoma. Previous studies of nivolumab combined with ipilimumab in metastatic melanoma ...

Bilateral ipilimumab-induced posterior uveitis following treatment for metastatic choroidal melanoma.

Ipilimumab is a CTLA-4 monoclonal antibody that amplifies T-cell activation and response to melanoma. It is approved to treat unresectable or metastatic melanoma. Immune-related adverse events are com...

Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients.

Immune checkpoint inhibitors are new therapeutic options for metastatic melanoma, but little data is available in organ transplant recipient populations. Six French patients, 3 men and 3 women, mean a...

Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study.

Immunotherapy is a well-established treatment option in patients with metastatic melanoma. However, biomarkers that can be used to predict a response in these patients have not yet been found, putting...

Granulomatous dermatitis associated with ipilimumab therapy (Ipilimumab associated granulomatous dermatitis).

Ipilimumab is a human monoclonal antibody that targets cytotoxic T-lymphocyte-associated antigen (CTLA-4) approved for treatment of metastatic melanoma. The most commonly reported side effects are imm...

Medical and Biotech [MESH] Definitions

An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

A combined vaccine used to prevent infection with diphtheria and tetanus toxoid. This is used in place of DTP vaccine (DIPHTHERIA-TETANUS-PERTUSSIS VACCINE) when PERTUSSIS VACCINE is contraindicated.

A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)

Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.

More From BioPortfolio on "A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....


Searches Linking to this Trial